4D Molecular Therapeutics announced on December 16, 2024, the landmark publication of preclinical data for its 4D-150 program in the Investigative Ophthalmology & Visual Science (IOVS) journal. This publication focuses on the treatment of neovascular retinopathies, providing scientific validation for the company's proprietary Therapeutic Vector Evolution platform.
The published data demonstrated that 4DMT's proprietary intravitreal vector, R100, exhibited superior transduction and transgene expression compared to AAV2, a standard AAV serotype used in retinal gene therapies. The R100 vector showed up to approximately a 10-fold improvement in all three human retinal cell types evaluated in vitro, as well as in all primary non-human primate retinal cell types.
This scientific validation underscores the technological differentiation of 4D-150 and its potential to deliver best-in-class customized vectors. The findings support the company's strategy to develop transformative genetic medicines for large market diseases, reinforcing the scientific basis for its lead candidate's clinical development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.